> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Nephron Pharmaceuticals Warehouse FDA-483
- URL: https://www.fdaweb.com/nephron-pharmaceuticals-warehouse-fda-483/
- Published: 2023-05-18T12:00:00.000Z
- Updated: 2026-09-14T18:33:06.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5154481

FDA has released the form FDA-483 issued following an 11/8-12/2/22 inspection at the Nephron Pharmaceuticals warehouse in Murray, KY. The four inspection observations were:

- failing to have a quality control unit;
- failing to examine visually at least once a year reserve samples from representative sample lots or batches of drug products selected by acceptable statistical procedures for evidence of deterioration;
- failing to train employees in written procedures required by current good manufacturing practice regulations; and
- failing to store drug products under appropriate conditions of humidity and light so their identity, strength, quality, and purity are not affected.